Warning lights
Signals from the annual accounts, the CBE and the Official Gazette, each with its threshold and source. No score, no verdict.
-
Negative equity NBB
More debt than assets in 3 of the last 4 fiscal years.
-
Two loss years in a row NBB
Negative result in 2024 and 2025.
-
Tight liquidity NBB
Cash and receivables cover 64 % of short-term debt in 2025; threshold 65 %.
Financials
Financial year 2025
3Pharma from Sint-Niklaas, company number BE0647600506, closed financial year 2025 with a result of € -3 after tax. For that financial year 3Pharma recorded a gross margin of € 84,337 and equity of € -18,557. Compared with financial year 2024, the result moved from € -6,072 to € -3. The company made a loss. More debts than assets. High debts against a small own buffer. The most recent annual accounts were filed with the National Bank of Belgium on June 11, 2026.
€ -18,557
Assets minus debts, by the books. What is left if everything were sold and paid today.
€ -3
▲ 100 % less loss than in 2024
Profit after tax over the fiscal year.
€ 34,725
▲ 73% vs 2024
Cash and bank balances on the last day of the fiscal year.
Loss, nothing to pay out
Reserves fell to € -37,157.
People and assets in 2025
€ 52,234
▼ 45% vs 2024
Payroll staff only. What the director pays themselves is already netted into the gross margin and is not shown separately in the accounts.
€ 1,089
▼ 79% vs 2024
Book value of vehicles, furniture and equipment.
Debts at end 2025
€ 62,779
▼ 25% vs 2024
€ 18,628 is repaid this year. At this pace the long-term loan is gone in ≈ 3 years.
€ 239,178
▼ 11% vs 2024
Supplier invoices still open on the last day of the fiscal year.
€ 20,719
▼ 39% vs 2024
Taxes, VAT and social contributions still to pay.
| 2022 | 2023 | 2024 | 2025 | Change 2024 → 2025 | |
|---|---|---|---|---|---|
| Gross margin | € 113,365 | € 97,205 | € 114,639 | € 84,337 | ▼ 26% |
| Profit after taxes | € 25,450 | € -21,594 | € -6,072 | € -3 | ▲ € 6,068 |
| Equity | € 9,112 | € -12,482 | € -18,554 | € -18,557 | |
| Total debts | € 487,432 | € 381,827 | € 395,990 | € 326,391 | ▼ 18% |
| Cash | € 105,103 | € 36,094 | € 20,112 | € 34,725 | ▲ 73% |
| Retained profit | € -9,488 | € -31,082 | € -37,154 | € -37,157 | |
| Bank debt | € 117,533 | € 71,606 | € 83,305 | € 62,779 | ▼ 25% |
| Balance sheet total | € 496,544 | € 369,345 | € 377,437 | € 307,833 | ▼ 18% |
| Employees (FTE) | 1.3 | - | - | - |
Key figures of 3Pharma, fiscal years 2022 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.
What happened to 3Pharma?
What happened at 3Pharma in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:
- New annual accounts for financial year 2025: loss of € 3. Source: NBB ↗
- Waelput Invest BV became a director. NBB
- Minnen-Luyten BV became a director. NBB
- Incorporation, published in the Gazette. Source: Staatsblad ↗
- New establishment in Sint-Niklaas. KBO
In short
From € 25,450 profit in 2022 to € 3 loss in 2025.
Best year ever: 2022, with € 25,450 profit.
On average € 87,200 of value added per employee in 2022.
Management
The stake of Waelput Invest comes from that shareholder’s own annual accounts; small companies do not report their shareholders themselves.
3PharmaBehind 3Pharma are Waelput Invest BV and Minnen-Luyten BV. The shares are held by Waelput Invest (50%).
Directors
According to the 2025 annual accounts
Director · represented by Bart Waelput
since 2017
Director · represented by Tomas Minnen
since 2017
Shareholders
50%
Participations
No participations in other companies reported.
Establishments
Establishment units
Physical locations of this company
Klein-Hulststraat 14
9100 Sint-Niklaas
What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.
Website
Technologies
Hosting & Email
Email provider
Microsoft 365
Hosting
CLOUDFLARENET - Cloudflare, Inc., US
Website info
Features
Security
Network
Shareholders according to the Official Gazette deeds
Who contributed at incorporation and at capital increases, with the deed as source. Later share transfers are not published in the Gazette.
Incorporation
Source: Deed ↗- Van Dijck-Voets Management(vennoot) 33.3%
- Minnen-Luyten(vennoot) 33.3%
- Farmeka(vennoot) 33.3%
Details
- Company number
- 0647.600.506
- VAT number
- BE 0647.600.506
- Registered office
- Klein-Hulststraat 14, 9100 Sint-Niklaas
- Names & denominations
- 3Pharma
- Enterprise type
- Rechtspersoon
- Legal form
- Private limited company
- Legal situation
- Normale toestand
- Start date
- 28 January 2016
- Peppol
- Active · Active since 23 Dec 2025
- Contact
- wameda.be
- Activities · NACE
Groothandel in farmaceutische en medische artikelen
Detailhandel in farmaceutische producten
Detailhandel in cosmetica en toiletartikelen
Detailhandel in medische en orthopedische artikelen, muv corrigerende brillen, lenzen en zonnebrillen
Detailhandel in medische en orthopedische artikelen in gespecialiseerde winkels